209 related articles for article (PubMed ID: 25081631)
1. A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck.
Adkins D; Ley J; Dehdashti F; Siegel MJ; Wildes TM; Michel L; Trinkaus K; Siegel BA
Cancer Med; 2014 Dec; 3(6):1493-501. PubMed ID: 25081631
[TBL] [Abstract][Full Text] [Related]
2. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
3. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.
Schmitz S; Hamoir M; Reychler H; Magremanne M; Weynand B; Lhommel R; Hanin FX; Duprez T; Michoux N; Rommel D; Lonneux M; Cappoen N; Gillain A; Machiels JP
Ann Oncol; 2013 Sep; 24(9):2261-6. PubMed ID: 23704200
[TBL] [Abstract][Full Text] [Related]
4. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
5. Early evaluation of neoadjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Nakamoto Y; Shinohara S; Fujiwara K; Yamazaki H; Kanazawa Y; Kurihara R; Kishimoto I; Harada H; Naito Y
Int J Clin Oncol; 2013 Jun; 18(3):402-10. PubMed ID: 22402886
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Contrast-Enhanced CT Versus ¹⁸F-FDG PET/CT Evaluation and the Prognostic Value of Extranodal Extension for Surgical Patients with Head and Neck Squamous Cell Carcinoma.
Lee JR; Choi YJ; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1020-7. PubMed ID: 26122372
[TBL] [Abstract][Full Text] [Related]
7. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
[TBL] [Abstract][Full Text] [Related]
8. Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?
Castaldi P; Rufini V; Bussu F; Miccichè F; Dinapoli N; Autorino R; Lago M; De Corso E; Almadori G; Galli J; Paludetti G; Giordano A; Valentini V
Radiother Oncol; 2012 Apr; 103(1):63-8. PubMed ID: 22459579
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of
Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
[TBL] [Abstract][Full Text] [Related]
10.
Verhoeff SR; van de Donk PP; Aarntzen EHJG; Oosting SF; Brouwers AH; Miedema IHC; Voortman J; Menke-van der Houven van Oordt WC; Boellaard R; Vriens D; Slingerland M; Hermsen R; Grunsven IVE; Heskamp S; van Herpen CML
J Nucl Med; 2022 Oct; 63(10):1523-1530. PubMed ID: 35512998
[TBL] [Abstract][Full Text] [Related]
11. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
[TBL] [Abstract][Full Text] [Related]
12. FDG PET/CT and diffusion-weighted imaging of head and neck squamous cell carcinoma: comparison of prognostic significance between primary tumor standardized uptake value and apparent diffusion coefficient.
Nakajo M; Nakajo M; Kajiya Y; Tani A; Kamiyama T; Yonekura R; Fukukura Y; Matsuzaki T; Nishimoto K; Nomoto M; Koriyama C
Clin Nucl Med; 2012 May; 37(5):475-80. PubMed ID: 22475897
[TBL] [Abstract][Full Text] [Related]
13. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
[TBL] [Abstract][Full Text] [Related]
14. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma.
Yi JS; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY; Roh JL
J Surg Oncol; 2012 Nov; 106(6):708-12. PubMed ID: 22674652
[TBL] [Abstract][Full Text] [Related]
16. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
17. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Lalami Y; Garcia C; Flamen P; Ameye L; Paesmans M; Awada A
Head Neck; 2016 Mar; 38(3):347-54. PubMed ID: 25332069
[TBL] [Abstract][Full Text] [Related]
19. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.
Moeller BJ; Rana V; Cannon BA; Williams MD; Sturgis EM; Ginsberg LE; Macapinlac HA; Lee JJ; Ang KK; Chao KS; Chronowski GM; Frank SJ; Morrison WH; Rosenthal DI; Weber RS; Garden AS; Lippman SM; Schwartz DL
J Clin Oncol; 2009 May; 27(15):2509-15. PubMed ID: 19332725
[TBL] [Abstract][Full Text] [Related]
20. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
